168 related articles for article (PubMed ID: 23707532)
1. HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain.
Ai M; Qiu S; Lu Y; Fan Z
Cell Signal; 2013 Sep; 25(9):1754-61. PubMed ID: 23707532
[TBL] [Abstract][Full Text] [Related]
2. Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.
Ai M; Liang K; Lu Y; Qiu S; Fan Z
Cancer Biol Ther; 2013 Mar; 14(3):237-45. PubMed ID: 23291984
[TBL] [Abstract][Full Text] [Related]
3. Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.
Falkenberg N; Anastasov N; Höfig I; Bashkueva K; Lindner K; Höfler H; Rosemann M; Aubele M
Mol Oncol; 2015 Jan; 9(1):282-94. PubMed ID: 25241146
[TBL] [Abstract][Full Text] [Related]
4. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
5. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.
Castro NE; Lange CA
Breast Cancer Res; 2010; 12(4):R60. PubMed ID: 20687930
[TBL] [Abstract][Full Text] [Related]
6. Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6.
Weaver AM; Silva CM
Breast Cancer Res; 2007; 9(6):R79. PubMed ID: 17997837
[TBL] [Abstract][Full Text] [Related]
7. Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer.
Ludyga N; Anastasov N; Gonzalez-Vasconcellos I; Ram M; Höfler H; Aubele M
Mol Biosyst; 2011 May; 7(5):1603-12. PubMed ID: 21380407
[TBL] [Abstract][Full Text] [Related]
8. Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cells.
Ludyga N; Anastasov N; Rosemann M; Seiler J; Lohmann N; Braselmann H; Mengele K; Schmitt M; Höfler H; Aubele M
Mol Cancer Res; 2013 Apr; 11(4):381-92. PubMed ID: 23364537
[TBL] [Abstract][Full Text] [Related]
9. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression.
Regan Anderson TM; Peacock DL; Daniel AR; Hubbard GK; Lofgren KA; Girard BJ; Schörg A; Hoogewijs D; Wenger RH; Seagroves TN; Lange CA
Cancer Res; 2013 Sep; 73(18):5810-20. PubMed ID: 23928995
[TBL] [Abstract][Full Text] [Related]
10. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Ostrander JH; Daniel AR; Lofgren K; Kleer CG; Lange CA
Cancer Res; 2007 May; 67(9):4199-209. PubMed ID: 17483331
[TBL] [Abstract][Full Text] [Related]
11. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.
Li X; Lu Y; Liang K; Hsu JM; Albarracin C; Mills GB; Hung MC; Fan Z
Oncogene; 2012 Oct; 31(40):4372-83. PubMed ID: 22231447
[TBL] [Abstract][Full Text] [Related]
12. Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.
Tsui T; Miller WT
Biochemistry; 2015 May; 54(20):3173-82. PubMed ID: 25940761
[TBL] [Abstract][Full Text] [Related]
13. Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells.
Ikeda O; Sekine Y; Mizushima A; Nakasuji M; Miyasaka Y; Yamamoto C; Muromoto R; Nanbo A; Oritani K; Yoshimura A; Matsuda T
J Biol Chem; 2010 Dec; 285(49):38093-103. PubMed ID: 20929863
[TBL] [Abstract][Full Text] [Related]
14. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.
Lofgren KA; Ostrander JH; Housa D; Hubbard GK; Locatelli A; Bliss RL; Schwertfeger KL; Lange CA
Breast Cancer Res; 2011 Sep; 13(5):R89. PubMed ID: 21923922
[TBL] [Abstract][Full Text] [Related]
15. Modulation by Syk of Bcl-2, calcium and the calpain-calpastatin proteolytic system in human breast cancer cells.
Fei B; Yu S; Geahlen RL
Biochim Biophys Acta; 2013 Oct; 1833(10):2153-64. PubMed ID: 23684705
[TBL] [Abstract][Full Text] [Related]
16. Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers.
Qiu L; Levine K; Gajiwala KS; Cronin CN; Nagata A; Johnson E; Kraus M; Tatlock J; Kania R; Foley T; Sun S
PLoS One; 2018; 13(6):e0198374. PubMed ID: 29879184
[TBL] [Abstract][Full Text] [Related]
17. BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.
Miah S; Goel RK; Dai C; Kalra N; Beaton-Brown E; Bagu ET; Bonham K; Lukong KE
PLoS One; 2014; 9(2):e87684. PubMed ID: 24523872
[TBL] [Abstract][Full Text] [Related]
18. In situ quantification of HER2-protein tyrosine kinase 6 (PTK6) protein-protein complexes in paraffin sections from breast cancer tissues.
Aubele M; Spears M; Ludyga N; Braselmann H; Feuchtinger A; Taylor KJ; Lindner K; Auer G; Stering K; Höfler H; Schmitt M; Bartlett JM
Br J Cancer; 2010 Aug; 103(5):663-7. PubMed ID: 20700126
[TBL] [Abstract][Full Text] [Related]
19. Breast tumor kinase (Brk/PTK6) plays a role in the differentiation of primary keratinocytes.
Tupper J; Crompton MR; Harvey AJ
Arch Dermatol Res; 2011 May; 303(4):293-7. PubMed ID: 21240512
[TBL] [Abstract][Full Text] [Related]
20. Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation.
Harvey AJ; Crompton MR
Oncogene; 2003 Aug; 22(32):5006-10. PubMed ID: 12902983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
